A mainstay of cancer treatment, doxorubicin is used as a standalone agent or in combination therapies, on-label and off, in at least 14 cancer types, including breast cancer, non-small cell lung cancer, and Wilms tumor.
YOU MAY BE INTERESTED IN
As artificial intelligence becomes an indispensable tool in cancer research, drug sponsors and researchers should focus on building and utilizing rich real-world evidence databases that can be used to complement clinical trials.
Two major cancer informatics companies—Flatiron Health and Caris Life Sciences—have created a partnership to generate combined biological and clinical real-world evidence datasets that can be used to inform the development of immuno-oncology agents and targeted cancer therapeutics.
St. Jude Children’s Research Hospital invested nearly $13 million toward a research collaboration with scientists at Columbia University, Duke University, and Stanford University to expand the understanding of G-protein coupled receptors, which are vital proteins that impact human health and disease.
A paper authored by members of an American Society of Clinical Oncology Task Force illuminates the importance of enabling patients to receive trial-related testing and care near their homes, rather than requiring patients to travel long distances to reach major research institutions.
The Pancreatic Cancer Action Network, or PanCAN, and the Global Coalition for Adaptive Research formed a strategic alliance to further advance research efforts for pancreatic cancer.